Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.62 |
| ▸ | CTSL | P07711 | 5/20 | 0.58 |
| ▸ | CTSB | P07858 | 5/20 | 0.58 |
| ▸ | CTSS | P25774 | 4/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.54 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8683812 | 1.00 | CTSK (0.62) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL8683808 | 1.00 | CTSK (0.62) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL7551174 | 1.00 | CTSK (0.62) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL27510729 | 0.91 | CTSK (0.58) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL1398980 | 0.91 | CTSK (0.58) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL1823902 | 0.90 | CTSK (0.76) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL2366985 | 0.90 | CTSK (0.76) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL222158 | 0.90 | CTSK (0.76) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL3584839 | 0.89 | CTSK (0.62) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL14422996 | 0.87 | CTSK (0.62) | CTSKCTSLCTSBCTSSATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020115721-A1 | Esters of alkycarboxy amino acids as prodrugs of modulators of the kainate receptor | ANNOVIS, INC. | 2002-08-22 | — | — | US | disclosed |
| WO-2002055479-A2 | ESTERS OF ALKYLCARBOXY AMINO ACIDS AS PRODRUGS OF MODULATORS OF THE KAINATE RECEPTOR | ANNOVIS, INC. (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115721-A1 | Esters of alkycarboxy amino acids as prodrugs of modulators of the kainate receptor | GRIK1, GRIK2, GRIK4 | CTSK 1600/4885CTSL 1528/4885CTSB 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.